News stories about ProPhase Labs (NASDAQ:PRPH) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProPhase Labs earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.7355805099685 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of ProPhase Labs (NASDAQ:PRPH) traded down $0.02 during trading hours on Friday, reaching $2.27. 8,600 shares of the company traded hands, compared to its average volume of 21,510. ProPhase Labs has a one year low of $1.78 and a one year high of $2.45. The firm has a market cap of $28.46, a P/E ratio of 2.97 and a beta of 0.18.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.05) earnings per share for the quarter. ProPhase Labs had a return on equity of 40.36% and a net margin of 307.58%. The business had revenue of $3.04 million during the quarter.

ProPhase Labs declared that its Board of Directors has authorized a stock buyback program on Friday, November 10th that allows the company to repurchase 1,700,000 outstanding shares. This repurchase authorization allows the company to buy shares of its stock through a tender offer. Stock repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Separately, ValuEngine downgraded shares of ProPhase Labs from a “hold” rating to a “sell” rating in a report on Thursday, October 5th.

In other news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $824,828.30. Following the sale, the chief financial officer now owns 132,703 shares of the company’s stock, valued at approximately $305,216.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ted William Karkus sold 364,950 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $2.30, for a total transaction of $839,385.00. Following the sale, the chief executive officer now directly owns 2,309,638 shares in the company, valued at approximately $5,312,167.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,423,255 shares of company stock worth $5,573,487. 29.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “ProPhase Labs (PRPH) Receiving Somewhat Favorable News Coverage, Analysis Finds” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Insider Buying and Selling by Quarter for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.